Leveraging the immune system during chemotherapy: Moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic

Cancer Research

Volumn 67, Issue 17, 2007, Pages 7941-7944

  Obeid, Michel ^a,b,c   Panaretakis, Theocharis ^a,b,c   Tesniere, Antoine ^a,b,c   Joza, Nick ^a,b,c   Tufi, Roberta ^a,b,c   Apetoh, Lionel ^b,c   Ghiringhelli, François ^b,c   Zitvogel, Laurence ^b,c   Kroemer, Guido ^a,b,c  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CALRETICULIN; CANCER VACCINE; CASPASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; IMATINIB; MITOMYCIN C; MITOXANTRONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CELL DEATH; CELL SURFACE; GAMMA IRRADIATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR CELL;

ANIMALS; ANTIGENS, SURFACE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CALRETICULIN; CELL DEATH; HUMANS; IMMUNE SYSTEM; MODELS, BIOLOGICAL;

EID: 34548570079     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1622     Document Type: Review

References (24)

1. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nat Rev Drug Discov 2007;6:115-20.
2. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006;5:649-59.
3. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev 2006;6:715-27.
4. Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol 2004;84:131-79.
5. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44.
6. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8.
7. Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006;12:214-9.
8. Obeid M, Panaretakis T, Joza N, et al. Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007. July 27 [Epub ahead of print].
9. Blachere NE, Morris HK, Braun D, et al. IL-2 is required for the activation of memory CD8+ T cells via antigen cross-presentation. J Immunol 2006;176:7288-300.
10. Lake RA, van der Most RG. A better way for a cancer cell to die. N Engl J Med 2006;354:2503-4.
11. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61.
12. Obeid M, Tesniere A, Panaretakis T, et al. Ectocalreticulin in immunogenic chemotherapy. Immunol Rev. In press.
13. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000;191:411-6.
14. Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol 2006;27:244-50.
15. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005;202:1691-701.
16. Williams DB. Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum. J Cell Sci 2006;119:615-23.
17. Gelebart P, Opas M, Michalak M. Calreticulin, a Ca2+-binding chaperone of the endoplasmic reticulum. Int J Biochem Cell Biol 2005;37:260-6.
18. Gardai SJ, McPhillips KA, Frasch SC, et al. Cellsurface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005;123:321-34.
19. Boyce M, Bryant KF, Jousse C, et al. A selective inhibitor of eIF2α dephosphorylation protects cells from ER stress. Science 2005;307:935-9.
20. Basu S, Srivastava PK. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med 1999;189:797-802.
21. Steinman RM, Mellman I. Immunotherapy: bewitched, bothered, and bewildered no more. Science 2004;305:197-200.
22. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Revision in Nature Medicine. In press.
23. Storkus WJ, Falo LD, Jr. A 'good death' for tumor immunology. Nat Med 2007;13:28-30.
24. Clarke C, Smyth MJ. Calreticulin exposure increases cancer immunogenicity. Nat Biotechnol 2007;25:192-3.